French pharma major Sanofi (Euronext: SAN) will present new results from a Phase III study of Dupixent (dupilumab) at the 2020 virtual congress of the European Respiratory Society (ERS).
Results from the open-label extension trial show that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in people with moderate-to-severe asthma.
New chief executive Paul Hudson has placed a strong focus on growing sales of Dupixent to boost the firm’s revenues, with a bold target of up to $12 billion in annual sales supported by a robust sales and marketing effort.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze